CDKN2A germline mutations in familial pancreatic cancer

Annals of Surgery

Volumn 236, Issue 6, 2002, Pages 730-737

  Bartsch, Detlef K ^a   Sina Frey, Mercedes ^a   Lang, Sven ^a   Wild, Anja ^a   Gerdes, Berthold ^a   Barth, Peter ^a   Kress, Ralf ^a   Grützmann, Robert ^b   Colombo Benkmann, Mario ^c   Ziegler, Andreas ^d   Hahn, Stephan A ^e   Rothmund, Matthias ^a   Rieder, Harald ^a   Fernandez Cruz, L ^f  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF LÜBECK   (Germany)

^e RUHR UNIVERSITY BOCHUM   (Germany)

^f Ruhr University Bochum ^*

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN; PROTEIN CDKN2A; PROTEIN P14; PROTEIN P16; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; DNA SEQUENCE; FAMILY; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; MALE; MELANOMA; MUTATION; NONSENSE MUTATION; ONSET AGE; PANCREAS CANCER; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BASE SEQUENCE; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, P16; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; GERMANY; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PEDIGREE; POLYMERASE CHAIN REACTION; PREVALENCE; RISK ASSESSMENT; SAMPLING STUDIES; SEX DISTRIBUTION;

EID: 0036895738     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-200212000-00005     Document Type: Article

References (47)

1. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland-Häiufigkeiten und Trends. 2. Ausgabe Saarbrücken, 1999.
2. Yeo CJ, Cameron JL. Prognostic factors in ductal pancreatic cancer. Langenbecks Arch Surg 1998; 383:129-133.
3. Lynch HT. Genetics and pancreatic cancer. Arch Surg 1994; 129:266-268.
4. Crowley KE, Aston CE, McNamara PJ, et al. Familial aggregation of other cancers in families with pancreatic cancer. Am J Hum Genet 1997; 61:A196.
5. Hruban RH, Petersen GM, Ha PK, et al. Genetics of pancreatic cancer: From genes to families. Surg Oncol Clin North Am 1998; 7:1-23.
6. Hruban RH, Petersen GM, Goggins M, et al. Familial pancreatic cancer. Ann Oncol 1999; 10(suppl 4):69-73.
7. Bartsch DK, Sina-Frey M, Ziegler A, et al. Update of familial pancreatic cancer in Germany. Pancreatology 2001; 1:510-516.
8. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. J Natl Cancer Inst 1997; 89:442-446.
9. Giardiello FM, Welsh SB, Hamilton SR, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316:1511-1514.
10. McKusick VA. Ataxia teleangiectatica. In: McKusick MA, ed. Mendelian Inheritance in Man, 9th Ed. Baltimore: John Hopkins University Press, 1990:68-78.
11. Lynch HT, Smyrk TC, Watson P, et al. Genetics, natural history, tumor spectrum, and pathology of hereditary non-polyposis colorectal cancer: An updated review. Gastroenterology 1993; 104:1535-1549.
12. Li FP, Fraumeni JF Jr. Soft tissue sarcomas, breast cancer, and other neoplasms: A familial syndrome? Ann Intern Med 1969; 71:747-752.
13. Johan G, Offerhaus A, Giardiello FM, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992; 102:1980-1982.
14. Phelan CM, Lancaster JM, Tonin P, et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet 1996; 13:120-122.
15. Bergmann W, Watson P, de Jong J, et al. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990; 61:932-936.
16. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-707.
17. Stott FJ, Bates S, James MC, et al. The alternative product from the human CDKN2a locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 1998; 17:5001-5014.
18. Rozenblum E, Schutte M, Goggins M, et al. Tumor suppressing pathways in pancreatic carcinomas. Cancer Res 1997; 57:1731-1734.
19. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: A familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995; 333:975-977.
20. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995; 333:970-974.
21. Moskaluk CA, Hruban H, Lietman A, et al. Novel germline p16(INK4) allele (Asp145Cys) in a family with multiple pancreatic carcinomas. Mutations in brief no. 148. Hum Mutat 1998; 12:70.
22. Rizos H, Puig S, Badenas C, et al. A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF. Oncogene 2001; 20:5543-5547.
23. Wright DK, Manos MM. Sample preparation from paraffin-embedded tissues. In: Innis MA, Gelfand DH, Sninsky JJ, et al, eds. PCR Protocols: A Guide to Methods and Applications. San Diego: Academic Press, 1990:153-158.
24. INK4a is a prognostic marker in resected ductal pancreatic cancer. Ann Surg 2002; 235:51-59.
25. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994; 8:15-21.
26. Ehrenthal D, Haeger L, Griffin T, et al. Familial pancreatic adenocarcinoma in three generations: A case report and review of the literature. Cancer 1987; 59:1661-1664.
27. Grajower MM. Familial pancreatic cancer. Ann Intern Med 1983; 98:111.
28. Finch MD, Howes N, Ellis I, et al. Hereditary pancreatitis and familial pancreatic cancer. Digestion 1997; 58:564-569.
29. Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7:738-744.
30. Lynch HT, Fitzsimmons ML, Smyrk TC. Familial pancreatic cancer: Clinicopathologic study of 18 nuclear families. Am J Gastroenterol 1990; 85:54-60.
31. Lynch HT, Fusaro L, Smyrk TC, et al. Medical genetic study of eight pancreatic cancer prone families. Cancer Invest 1995; 13:141-149.
32. INK4a function. Nat Genet 1995; 10:114-116.
33. Pollock PM, Pearson JV, Hayward NK. Compilation of somatic mutations of the CDKN2 gene in human cancers: Non-random distribution of base substitutions. Genes Chromosome Cancer 1996; 15:77-88.
34. Lal G, Liu G, Schmocker B, et al. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 2000; 60:409-416.
35. Lynch HT, Krush AJ. Heredity and malignant melanoma: Implications for early cancer detection. Can Med Assoc J 1968; 99:17-21.
36. Gruis NA, Sandkuijl LA, van der Velden PA, et al. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families. Melanoma Res 1995; 5:169-177.
37. Goldstein AM, Tucker MA. Screening for CDKN2a mutations in hereditary melanoma. J Natl Cancer Inst 1997; 89:676-677.
38. Ghiorzo P, Ciotto P, Martelli M, et al. Characterization of lingurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999; 83:441-448.
39. Ciotti P, Strigini P, Bianchi-Scarra G. Familial melanoma and pancreatic cancer. N Engl J Med 1996; 334:468-469.
40. Borg A, Sandberg T, Nilson K, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2a mutation-positive melanoma families. J Natl Cancer Inst 2000; 92:1260-1266.
41. Lynch HT, Brand RE, Hogg D, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families. The familial atypical multiple mole melanoma-pancreatic carcinoma syndrome. Cancer 2002; 94:84-96.
42. Gerdes B, Bartsch DK, Ramaswamy A, et al. Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients? Pancreas 2000; 21:369-375.
43. Rulyak SJ, Lowenfels AB, Maisonneuve P, et al. Smoking as a risk factor in familial pancreatic cancer kindreds. Pancreatology 2001; 1:551.
44. Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2a and CDK4 mutations. J Natl Cancer Inst 2000; 92:1006-1010.
45. Lynch HAT, Randall EB, Lynch JF, et al. Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 2000; 119:1756-1760.
46. Rulyak SJ, Brentnall TA. Inherited pancreatic cancer: Surveillance and treatment strategies for affected families. Pancreatology 2001; 1:477-485.
47. Gerdes B, Kress R, Rieder H, et al. Familiäres pankreaskarzinom: Studienkonzept einer nationalen fallsammlung mit früherkennungsprogramm für hochrisikopersonen. Zae FQ 2002; 96:253-257.